The brief
- Nov 2023: the FDA's vet center accepted that LOY-001 can reasonably be expected to work: a first for any lifespan drug.
- Jan 2026: FDA accepted LOY-002's safety section; manufacturing is the last big section before conditional approval.
- Conditional approval would allow sales while the STAY study of over 1,000 senior dogs continues.
Technical approach
Biology
Slowing metabolic aging
LOY-002 targets metabolism that goes wrong with age; LOY-001/003 lower IGF-1, a hormone linked to big dogs' shorter lives.
Pathway
Sell now, prove fully later
Conditional approval lets a vet drug be sold for up to five years once safety and manufacturing are proven, while full proof is collected.
Trial
Trial in real pet dogs
STAY is a years-long study in pet dogs at vet clinics, pill vs placebo, measuring how long they live.
Programs
Loyal, two programs
Updated 24d agoLOY-002A beef-flavored daily pill for dogs aged 10+, meant to extend healthy life by improving metabolism that declines with age.DeployNextManufacturing section acceptedUpdated 11 Feb 2026View program →LOY-001 / LOY-003Drugs that lower IGF-1, the growth hormone that makes big breeds big and is linked to their shorter lives.PilotNextRemaining FDA sectionsUpdated 24d agoView program →
Research · Proto · Pilot · Deploy · Scaling
Research & demos
- Nov 2023
First sign regulators will judge a lifespan claim.
Open technical problems
- Proving dogs live longerOpen
Lifespan trials take years; the size of the effect is uncertain and dogs die of many causes.
- Will it work in people?Open
Dogs share our homes and diseases, but whether a dog lifespan drug predicts human benefit is untested.
Company & funding
- Raised
- $67Mdisclosed private rounds
- Last round
- FinancingFeb 2025
- HQ
- US
- Founded
- 2019
- Website
- loyal.com (opens loyal.com)
| Date | Round | Amount | Post-money | Lead |
|---|---|---|---|---|
| Feb 2025 | Financing | $22M | — | — |
| Mar 2024 | Series B | $45M | — | — |
People
- Celine HaliouaFounder and CEO